Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Co-Diagnostics Inc. (CODX), a molecular diagnostics developer focused on infectious disease and precision testing solutions, is trading at $1.39 as of 2026-04-13, marking a 1.09% gain in the latest trading session. This analysis outlines key market context, technical levels, and potential price scenarios for the stock in the near term, with no recent earnings data available for the company as of this writing. While CODX has traded in a relatively tight range in recent weeks, shifts in sector sen
Is Co-Diag (CODX) Stock Undervalued Now | Price at $1.39, Up 1.09% - Undervalued Stocks
CODX - Stock Analysis
4475 Comments
1505 Likes
1
Nachman
Regular Reader
2 hours ago
Market participants are evaluating earnings reports, which are contributing to selective sector movements.
👍 53
Reply
2
Lenox
Regular Reader
5 hours ago
Investors are monitoring global and domestic news, contributing to fluctuating market sentiment.
👍 50
Reply
3
Lish
Consistent User
1 day ago
I understood enough to hesitate.
👍 39
Reply
4
Sulmy
Senior Contributor
1 day ago
Missed the perfect timing…
👍 11
Reply
5
Radyn
Community Member
2 days ago
This feels like something I’ll think about later.
👍 230
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.